Komori
General Meetings of Shareholders4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice of Convocation of the 16th Annual General Meeting of Shareholders

The 16th Annual General Meeting of Shareholders will be held on 26 June 2026, with proposals submitted for the election of directors and statutory auditors, as well as a capital reduction without consideration and disposition of surplus to eliminate the deficit. All 6 director nominees are scheduled for reappointment, while 1 of the 3 statutory auditor nominees is scheduled for first-time appointment.

Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
11557239
¥ thousand
Wording
Conditional
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (16th)
2026
Jun 26
Date and time23 days from this disclosure to the meeting
Matters for resolution4 items

  1. Election of 6 directors

  2. Election of 3 corporate auditors

  3. Election of 1 Alternate Audit & Supervisory Board Member

  4. Reduction of the amounts of capital and capital reserves, and disposition of surplus

Shareholder Proposal

None (not specified)

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee
6Nominees
0New
3Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (16th)
Date and time10:00 a.m., Friday, 26 June 2026
Matters for resolutionProposal No. 1: Election of 6 directors, Proposal No. 2: Election of 3 corporate auditors, Proposal No. 3: Election of 1 Alternate Audit & Supervisory Board Member, Proposal No. 4: Reduction of the amounts of capital and capital reserves, and disposition of surplus
Shareholder ProposalNone (not specified)
Director nominee6, including 0 new and 3 outside directors
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To cover the ¥11,557,239 thousand deficit in retained earnings carried forward and strengthen the Company’s financial position.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 16th Annual General Meeting of Shareholders | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori